SCHEDULE: North Run Capital Reports 7.8% Stake in TELA Bio

North Run Capital, LP and affiliated entities report a passive beneficial ownership of 7.8% of TELA Bio, Inc.'s common stock as of September 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of TELA Bio, Inc. common stock.
• The reporting persons, including North Run Capital, LP, North Run Advisors, LLC, North Run - Due North Partners, LP, North Run GP, LP, Todd B. Hammer, Thomas B. Ellis, and Michael Bosco, collectively beneficially own 3,528,296 shares of common stock.
• This ownership stake represents approximately 7.8% of the outstanding shares of TELA Bio, Inc. common stock as of September 30, 2026.
• The filing states that these shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a passive ownership stake without new strategic information or significant changes in holdings.

Positives

• The reporting entities hold a significant stake (7.8%) in TELA Bio, Inc., which could indicate confidence in the company's long-term prospects.
• The filing confirms a passive investment approach, suggesting no immediate intent to disrupt current management or strategy.

Negatives

• The filing does not provide any new strategic insights or operational updates for TELA Bio, Inc.
• The ownership stake, while significant, does not represent a controlling interest.

Risks

• Potential for future changes in ownership strategy by North Run Capital and its affiliates, although currently stated as passive.
• Market perception of TELA Bio, Inc. could be influenced by the passive stake of a significant institutional investor, but without further strategic alignment, the impact is uncertain.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from TELA Bio, Inc. It solely reports on the ownership stake of North Run Capital and its affiliates.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates North Run Capital's established position in TELA Bio, Inc., but without additional context on their investment thesis or any active engagement, its broader industry implications are limited.

Stakeholder Impact

• Shareholders: The filing confirms a significant passive investor, which may be viewed positively for stability, but offers no immediate catalyst for share price appreciation.
• Management: The passive nature of the stake suggests no immediate pressure for changes in corporate strategy or governance from this investor.
• Creditors: No direct impact is indicated.

Next Steps

• Continued monitoring of North Run Capital's ownership and any potential changes in their investment strategy.
• Observation of TELA Bio, Inc.'s future financial performance and strategic announcements.

Key Dates

Keywords

TELA Bio, North Run Capital, Schedule 13G, Beneficial Ownership, Investment Management, Passive Stake, Common Stock